Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 131-I-meta-iodobenzylguanidine Clear all
Available No phase listed Expanded access

Expanded Access Protocol Using 131I-MIBG

NCT01590680
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma, Paraganglioma
Interventions
I-131 MIBG
Radiation
Lead sponsor
Jubilant DraxImage Inc.
Industry
Eligibility
12 Months and older
U.S. locations
19
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

NCT00253435
View directory record Official record
Conditions
Neuroblastoma
Interventions
Filgrastim, Carboplatin, Etoposide, Melphalan, Peripheral blood stem cell infusion, 131I-MIBG, Radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 29 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 2 Interventional

131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

NCT00293319
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, iobenguane I 131
Biological · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Year and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
San Francisco, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Oct 5, 2026, 5:58 PM EDT
Available No phase listed Expanded access

131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

NCT01163383
View directory record Official record
Conditions
Neuroblastoma, Childhood Metastatic Pheochromocytoma
Interventions
131 I-Metaiodobenzylguanidine (131 I-MIBG), 131 I-MIBG
Drug
Lead sponsor
John Maris
Other
Eligibility
1 Year and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Recruiting Phase 2 Interventional

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

NCT00107289
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
iobenguane I 131
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Recruiting Not applicable Interventional

MCT for the Harvard/UCSF ROBIN Center

NCT06000787
View directory record Official record
Conditions
Glioma, Childhood Brainstem, Neuroblastoma
Interventions
External beam radiotherapy, 131I-Metaiodobenzylguanidine (MIBG)
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Active, not recruiting Early Phase 1 Interventional

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

NCT03044977
View directory record Official record
Conditions
Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
Interventions
90Y-DOTA-3-Tyr-Octreotide, 131I-MIBG
Drug
Lead sponsor
David Bushnell
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 1 Interventional

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

NCT00083135
View directory record Official record
Conditions
Neuroblastoma
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, iobenguane I 131
Biological · Procedure · Radiation
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

NCT01377532
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
131 I-Metaiodobenzylguanidine (131 I-MIBG)
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 5, 2026, 5:58 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NCT03126916
View directory record Official record
Conditions
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 30 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
152
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

NCT00458952
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Ultratrace Iobenguane (MIBG) I 131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Not applicable Interventional

MIBG for Refractory Neuroblastoma and Pheochromocytoma

NCT01850888
View directory record Official record
Conditions
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
Interventions
131 I-Metaiodobenzylguanidine (131I-MIBG), Potassium iodide solution, G-CSF, hematopoietic stem cell infusion
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 5, 2026, 5:58 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma

NCT00992173
View directory record Official record
Conditions
Neuroblastoma
Interventions
Ultratrace Iobenguane I 131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 5, 2026, 5:58 PM EDT
Withdrawn Phase 1Phase 2 Interventional

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

NCT04614766
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
Interventions
Lutathera, Azedra
Drug
Lead sponsor
David Bushnell
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 5, 2026, 5:58 PM EDT
Not listed Phase 2 Interventional Results available

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

NCT00874614
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Ultratrace® Iobenguane I131
Radiation
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2020 · Synced Oct 5, 2026, 5:58 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

NCT02961491
View directory record Official record
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Ultratrace Iobenguane I131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
3
States / cities
Iowa City, Iowa • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 2 Interventional

131MIBG to Treat Malignant Pheochromocytoma

NCT00028106
View directory record Official record
Conditions
Pheochromocytoma
Interventions
[131]I-MIBG, 6-[18F]Fluorodopamine, [123]I-MIBG
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 5, 2026, 5:58 PM EDT
Available No phase listed Expanded access

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

NCT03015844
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
131-I-meta-iodobenzylguanidine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
365 Days to 29 Years
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

NCT01838187
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma, Paraganglioma
Interventions
I-131 MIBG, Vorinostat
Radiation · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months and older
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 2 Interventional Results available

N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma

NCT00659984
View directory record Official record
Conditions
Neuroblastoma
Interventions
UltratraceTM Iobenguane I 131 Imaging, UltratraceTM Iobenguane I 131 Therapy
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 30 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 5, 2026, 5:58 PM EDT
Active, not recruiting Phase 2 Interventional

MIBG Therapy for Patients With MIBG Avid Tumors

NCT02378428
View directory record Official record
Conditions
MIBG Avid Tumors
Interventions
MIBG
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Months to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Not applicable Interventional

Combination Targeted Radiotherapy in Neuroendocrine Tumors

NCT01099228
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
131-I MIBG and 111-In pentetreotide, 131-I MIBG and In-111 DOTATATE
Other
Lead sponsor
David Bushnell
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 5, 2026, 5:58 PM EDT
Not yet recruiting Phase 2 Interventional

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

NCT07261241
View directory record Official record
Conditions
Neuroblastoma
Interventions
Radiation: 131I-MIBG, Dinutuximab, Vorinostat
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 5, 2026, 5:58 PM EDT
Completed Phase 1 Interventional Results available

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

NCT01175356
View directory record Official record
Conditions
Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, External Beam Radiation Therapy, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Intensity-Modulated Radiation Therapy, Iobenguane I-131, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Pharmacological Study, Questionnaire Administration, Therapeutic Conventional Surgery, Topotecan Hydrochloride, Vincristine Sulfate
Radiation · Procedure · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 5, 2026, 5:58 PM EDT